<DOC>
	<DOCNO>NCT00379132</DOCNO>
	<brief_summary>This study design evaluate ability intravenously ( IV ) administer 131-I-labeled TM-601 ( chlorotoxin ) provide tumor-specific localization ( via radiographic image ) patient recurrent refractory primary solid tumor evidence metastatic involvement . ( Refractory tumor non-responsive standard treatment . ) The safety tolerability IV administer 131-I-TM-601 patient population evaluate part study .</brief_summary>
	<brief_title>131-I-TM-601 Study Adults With Solid Tumors</brief_title>
	<detailed_description>This multi-center , open label , non-randomized , sequential , within-patient dose-escalation study patient recurrent refractory primary solid tumor metastatic involvement ( include brain metastasis ) . Patients administer 1 3 ( Test Doses A , B Dose C ) escalate dose 131-I-TM-601 intravenous ( IV ) administration , dosimetry ( imaging-based evaluation dose reach target site ) conduct prior follow administration dose . Whole body dosimetry critical structure include , limited , bone marrow , bladder , brain , liver , thyroid determine . The preliminary result Test Dose Levels ( A and/or B ) patient analyze prior treat patient Dose C. Patients follow 28 day follow final dose , complete clinical assessment image evaluation final follow-up visit .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm recurrent refractory primary solid tumor malignancy . Primary tumor cell type one following : breast , nonsmall cell lung , melanoma , colorectal , prostatic adenocarcinoma ( hormone refractory ) glioma . Note : Patients primary solid tumor cell type list , meet selection criterion may consider eligible , case case basis Demonstration distant metastatic involvement see standard clinical noninvasive imaging technique ( CT/MRI ) biopsy . Note : casebycase basis , patient locally recurrent , unresectable ( inoperable ) tumor may consider inclusion Refractory standard curative treatment At least 18 year age Baseline Karnofsky Performance Status ( KPS ) 60100 % Life expectancy , base investigator judgement , great 3 month Adequate organ marrow function ( define protocol ) Women childbearing potential must negative pregnancy test , refrain nursing , must agree use appropriate contraception duration trial Prior cytotoxic chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study Patients sufficiently recover adverse event due previously administer agent Concurrent treatment investigational commercial agent therapy administer intent treat patient 's malignancy , include chemotherapy , immunotherapy , biological response modifier , palliative radiotherapy . Possible exception ( discretion investigator ) hormonal therapy breast prostate cancer , hematologic , analgesic , biphosphonate , form supportive therapy . History allergic reaction attribute compound similar chemical biologic composition 131Ilabeled chlorotoxin ( e.g . iodine iodinecontaining drug ) Patients uncontrolled intercurrent illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Glioma</keyword>
	<keyword>prostatic</keyword>
	<keyword>breast</keyword>
	<keyword>non-small cell lung</keyword>
	<keyword>melanoma</keyword>
	<keyword>colorectal</keyword>
	<keyword>pancreatic</keyword>
</DOC>